---
figid: PMC5701508__ott-10-5491Fig1
figtitle: 'The crossroads of breast cancer progression: insights into the modulation
  of major signaling pathways'
organisms:
- NA
pmcid: PMC5701508
filename: ott-10-5491Fig1.jpg
figlink: /pmc/articles/PMC5701508/figure/f1-ott-10-5491/
number: F1
caption: 'ER genomic pathway.Notes: (A) E2–ER activates gene expression through direct
  binding to specific ERE sequences, recruiting coactivators (CoAs) and histone acetyltransferases
  (HATs) (1); ER and E2 modulate gene expression through interactions with other transcription
  factors (TFs) (2); ER ligand-independent activation through receptor tyrosine kinase
  (RTK) signaling (3). (B) In breast cancer, the microenvironment containing fibroblasts
  and inflammatory and endothelial cells has a critical role in the initiation and
  progression of tumors, providing growth factors, cytokines, and chemokines that
  activate ER and upregulate its target genes. (C) ER nongenomic pathway. ER localizes
  at the cell membrane in caveolae, binds Cav1 and interacts with adaptor proteins/cSrc.
  This complex activates MAPK and PI3K–Akt pathways (1). E2/GPER at the cell membrane
  and endoplasmic reticulum activates cSrc signaling, releasing HB-EGF, which binds
  to EGFR and activates MAPK/PI3K–Akt pathways (2). ER associates with RTKs in response
  to E2 binding. E2–ER recruits additional coactivator molecules, leading to the activation
  of RTKs and the downstream kinase pathway (3).'
papertitle: 'The crossroads of breast cancer progression: insights into the modulation
  of major signaling pathways.'
reftext: Fernando J Velloso, et al. Onco Targets Ther. 2017;10:5491-5524.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9257681
figid_alias: PMC5701508__F1
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC5701508__F1
ndex: d577a14a-df0c-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5701508__ott-10-5491Fig1.html
  '@type': Dataset
  description: 'ER genomic pathway.Notes: (A) E2–ER activates gene expression through
    direct binding to specific ERE sequences, recruiting coactivators (CoAs) and histone
    acetyltransferases (HATs) (1); ER and E2 modulate gene expression through interactions
    with other transcription factors (TFs) (2); ER ligand-independent activation through
    receptor tyrosine kinase (RTK) signaling (3). (B) In breast cancer, the microenvironment
    containing fibroblasts and inflammatory and endothelial cells has a critical role
    in the initiation and progression of tumors, providing growth factors, cytokines,
    and chemokines that activate ER and upregulate its target genes. (C) ER nongenomic
    pathway. ER localizes at the cell membrane in caveolae, binds Cav1 and interacts
    with adaptor proteins/cSrc. This complex activates MAPK and PI3K–Akt pathways
    (1). E2/GPER at the cell membrane and endoplasmic reticulum activates cSrc signaling,
    releasing HB-EGF, which binds to EGFR and activates MAPK/PI3K–Akt pathways (2).
    ER associates with RTKs in response to E2 binding. E2–ER recruits additional coactivator
    molecules, leading to the activation of RTKs and the downstream kinase pathway
    (3).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Egfr
  - ras
  - Ras64B
  - Ras85D
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - frk
  - Hrb27C
  - betaTub60D
  - Rpt5
  - DCTN2-p50
  - Rel
  - mrn
  - ix
  - Coa
  - hat
  - Elp3
  - CG1894
  - chm
  - era
  - AP-1gamma
  - Jra
  - kay
  - Sp1
  - grass
  - Spn42Dd
  - Mmp1
  - MKP-4
  - p38b
  - rl
  - Src64B
  - ca
  - Myb
  - Taf5
  - l(1)G0020
  - Taf4
  - Rpn2
  - Sap-r
  - bsk
  - Raf
  - Dsor1
  - Mtk
  - Pka-C1
  - Pka-R2
  - Pka-C3
  - Pka-R1
  - Pka-C2
  - EGFR
  - ERBB2
  - IGF1R
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - FRK
  - REL
  - CRE1
  - CD40
  - ARHGEF7
  - ASCC1
  - H3P40
  - RELA
  - FKBP4
  - GTF2H4
  - NFKB2
  - PMPCB
  - PSIP1
  - H3P42
  - ESR2
  - TMPRSS11D
  - ESR1
  - ERAL1
  - FOS
  - FOSB
  - JUN
  - JUNB
  - JUND
  - FOSL1
  - FOSL2
  - SP1
  - PSG1
  - DAND5
  - HBEGF
  - GPER1
  - MMP1
  - MMP2
  - MMP3
  - MMP7
  - MMP8
  - MMP9
  - MMP10
  - MMP11
  - MMP12
  - MMP13
  - MMP14
  - MMP15
  - MMP16
  - MMP17
  - MMP19
  - MMP20
  - MMP21
  - MMP23B
  - MMP24
  - MMP25
  - MMP26
  - MMP27
  - MMP28
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - SRC
  - PTK2B
  - CAV1
  - CBFA2T2
  - PPP1R13B
  - PPP1R12C
  - CUX1
  - SART3
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - NOS3
  - ENO4
  - Estradiol
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
